
PRODUCT INFORMATION

KS370G

Item No. 46450

CAS Registry No.:	105955-01-9
Formal Name:	3-(3,4-dihydroxyphenyl)-N-(2-phenylethyl)-2-propenamide
Synonyms:	Caffeic Acid phenylethyl amide, Caffeoylphenethylamine, CFPA
MF:	$C_{17}H_{17}NO_3$
FW:	283.3
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

KS370G is supplied as a solid. A stock solution may be made by dissolving the KS370G in the solvent of choice, which should be purged with an inert gas. KS370G is soluble (≥10 mg/ml) in ethanol and DMSO.

Description

KS370G is a synthetic caffeamide and the amide-containing derivative of caffeic acid phenylethyl ester (Item No. 70750).[1-4] It inhibits matrix metalloproteinase-2 (MMP-2) and MMP-9 (IC_{50}s = 8.2 and 7.28 nM, respectively) and has antioxidant activity in cell-free assays.[5,6] KS370G inhibits viral replication in porcine alveolar macrophages infected with porcine reproductive and respiratory syndrome virus (PRRSV).[7] It decreases LPS- and IFN-γ-induced production of nitric oxide (NO) and prostaglandin E_2 (PGE_2; Item No. 14010) in BV-2 microglia at 0.35-3.5 µM.[1] KS370G decreases left ventricular hypertrophy and reverses left ventricular function impairments induced by abdominal aortic constriction in mice.[2] It also decreases plasma glucose levels and increases plasma insulin levels in normal and diabetic mice.[3] Additionally, KS370G (10 mg/kg) decreases renal fibrosis in a mouse model of renal ischemia-reperfusion injury.[4]

References

1. Lu, D.Y., Huang, B.R., Yeh, W.L., *et al.* Anti-neuroinflammatory effect of a novel caffeamide derivative, KS370G, in microglial cells. *Mol. Neurobiol.* **48(3)**, 863-874 (2013).
2. Weng, Y.C., Chuang, C.F., Chuang, S.T., *et al.* KS370G, a synthetic caffeamide derivative, improves left ventricular hypertrophy and function in pressure-overload mice heart. *Eur. J. Pharmacol.* **684(1-3)**, 108-115 (2012).
3. Weng, Y.C., Chiu, H.L., Lin, Y.C., *et al.* Antihyperglycemic effect of a caffeamide derivative, KS370G, in normal and diabetic mice. *J. Agric. Food Chem.* **58(18)**, 10033-10038 (2010).
4. Chuang, S.T., Kuo, Y.H., and Su, M.J. Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. *Sci. Rep.* **4**, 5814 (2014).
5. Shi, Z.H., Li, N.G., Shi, Q.P., *et al.* Synthesis and structure–activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors. *Bioorg. Med. Chem. Lett.* **23(5)**, 1206-1266 (2013).
6. Yang, Y., Song, Z.-G., and Liu, Z.-Q. Synthesis and antioxidant capacities of hydroxyl derivatives of cinnamoylphenethylamine in protecting DNA and scavenging radicals. *Free Radic. Res.* **45(4)**, 445-453 (2011).
7. He, Z., Nie, Z., Liao, J., *et al.* Identification of compounds targeting porcine reproductive and respiratory syndrome virus nsp3 and evaluation of their antiviral efficacy. *Virulence* **16(1)**, 2530176 (2025).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/22/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM